Richard Kim, MD, Moffitt Cancer Center
Advertisement
Articles by Richard Kim, MD, Moffitt Cancer Center
Advertisement
Latest Updated Articles
Updates in Frontline Treatment of Metastatic Liver CancerPublished: July 24th 2020 | Updated:
Initiation of Systemic Therapy for mHCCPublished: July 24th 2020 | Updated:
Overview and Diagnosis of HCCPublished: July 24th 2020 | Updated:
mHCC: Influence of PD-L1 Inhibitors on Second-Line TherapyPublished: July 24th 2020 | Updated:
ASCO 2020 Data for Treatment of Advanced HCCPublished: July 24th 2020 | Updated:
Role of VEGF TKIs for Treatment of HCCPublished: July 24th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5